ReviewHuman vaccines & immunotherapeutics2026
Overview of adult immunization in Finland: Successes, lessons learned and the way forward.
Review in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The exchange of knowledge and best practices is essential for improving adult vaccination strategies across the European region. Finland serves as a valuable example, with a centralized, publicly funded National Vaccination Program (NVP) supported by national evaluation for decision-making based on comprehensive population-based registers. These registers enable assessment of disease burden, facilitate the identification of high-risk groups, and enable evaluating vaccination coverage, impact, and safety during the implementation. The NVP allows a centralized tender with lower vaccine prices, centralized vaccine procurement, and uniform processes for vaccine administration by public health care. Despite these strengths, Finland faces challenges in adult vaccination similar to other EU countries, including budgetary constraints, as well as the need for improved implementation, especially for high-risk groups. The complex evaluation, decision, funding, and procurement process causes delays in vaccine introduction into the NVP. This review describes Finland's adult vaccination system, from policy to implementation, drawing on a structured search of PubMed/MEDLINE, gray literature (2009-2024) and expert input. While there are areas for further improvement, Finland's commitment to provide cost-effective, equitable, evidence-based vaccination programs with high coverage, including for at-risk subpopulations, ensures continued progress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.